Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy-Reference-Cited by-同舟云学术

Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy

Published:2011-05-03 Issue:9 Volume:154 Page:573
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Hanania Nicola A.¹,Alpan Oral¹,Hamilos Daniel L.¹,Condemi John J.¹,Reyes-Rivera Irmarie¹,Zhu Jin¹,Rosen Karin E.¹,Eisner Mark D.¹,Wong Dennis A.¹,Busse William¹

Affiliation:

1. From Baylor College of Medicine, Houston, Texas; O & O Alpan, Bethesda, Maryland; Massachusetts General Hospital, Boston, Massachusetts; AAIR Research Center, Rochester, New York; Genentech, South San Francisco, California; and University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Cited by 485 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers and clinical outcomes after tezepelumab cessation;Annals of Allergy, Asthma & Immunology;2024-09

2. Model‐based comparisons of post‐treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union;British Journal of Clinical Pharmacology;2024-08-07

3. Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study;American Journal of Respiratory and Critical Care Medicine;2024-08-01

4. Molecular Pathways and Potential Therapeutic Targets of Refractory Asthma;Biology;2024-08-01

5. Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial;Frontiers in Immunology;2024-07-29